By Milind Javle, M.D., associate professor, Department of Gastrointestinal (GI) Medical Oncology, MD Anderson Cancer Center
Recently, a clinical trial published in the New England Journal of Medicine has offered new hope for patients suffering from pancreatic cancer.
This trial enrolled over 300 patients with advanced cancer of the pancreas, who were treated with either the standard chemotherapy with gemcitabine or with a four-drug chemotherapy combination called FOLFIRINOX.
A five-month improvement in survival was noted with FOLFIRINOX; this regimen also delayed cancer progression. This study is important because for the first time a drug combination has been shown to extend survival of pancreatic cancer patients by a significant degree over that offered by gemcitabine, alone.
Recently, a clinical trial published in the New England Journal of Medicine has offered new hope for patients suffering from pancreatic cancer.
This trial enrolled over 300 patients with advanced cancer of the pancreas, who were treated with either the standard chemotherapy with gemcitabine or with a four-drug chemotherapy combination called FOLFIRINOX.
A five-month improvement in survival was noted with FOLFIRINOX; this regimen also delayed cancer progression. This study is important because for the first time a drug combination has been shown to extend survival of pancreatic cancer patients by a significant degree over that offered by gemcitabine, alone.
Continue reading New Hope For Treating Pancreatic Cancer.
No comments:
Post a Comment